EVE Health Group Limited (ASX:EVE)

Australia flag Australia · Delayed Price · Currency is AUD
0.0210
+0.0010 (5.00%)
Mar 10, 2026, 1:59 PM AEST
-47.50%
Market Cap 5.70M
Revenue (ttm) 1.36M
Net Income (ttm) -1.62M
Shares Out 284.88M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 542,213
Average Volume 196,969
Open 0.0200
Previous Close 0.0200
Day's Range 0.0200 - 0.0210
52-Week Range 0.0180 - 0.0400
Beta 0.29
RSI 53.54
Earnings Date Feb 26, 2026

About EVE Health Group

EVE Health Group Limited, together with its subsidiaries, engages in the development, retail, and commercialization of health and wellness, and pharmaceutical products. The company lead product is Dyspro, a proprietary pharmaceutical-grade formulation to address dysmenorrhea (menstrual pain); and Libbo, a proprietary pharmaceutical-grade oral dissolving film formulation for the treatment of erectile dysfunction. It also offers Lactobacillus rhamnosus Beebiotic MAP01, a proprietary strain to support digestive health and vitality. The company was... [Read more]

Industry Packaged Foods
Founded 2003
Employees 3
Stock Exchange Australian Securities Exchange
Ticker Symbol EVE
Full Company Profile

Financial Performance

In fiscal year 2025, EVE Health Group's revenue was 1.73 million, a decrease of -18.70% compared to the previous year's 2.13 million. Losses were -1.58 million, -16.89% less than in 2024.

Financial Statements

News

There is no news available yet.